Okay, let's tackle this question. The patient is on cisplatin therapy and has intractable vomiting on the third day. The question is asking for the agent of choice to control this vomiting.

First, I need to recall the types of chemotherapy-induced nausea and vomiting (CINV). Cisplatin is a highly emetogenic drug. The vomiting usually occurs in two phases: acute (within the first 24 hours) and delayed (24-120 hours after treatment). The question mentions the third day, so that's the delayed phase.

For delayed CINV, the mainstay of treatment is a 5-HT3 receptor antagonist plus a neurokinin-1 (NK1) receptor antagonist. The 5-HT3 antagonists like ondansetron are used in the acute phase, but for delayed, the NK1 antagonists such as aprepitant are crucial. So the combination would be a 5-HT3 antagonist plus aprepitant. However, if the options include aprepitant, that's the key.

Looking at the options, even though they aren't listed here, I know that aprepitant is the NK1 antagonist used for delayed emesis. So if one of the options is aprepitant, that's the correct answer. The other options might include metoclopramide (dopamine antagonist, not effective for delayed CINV), dexamethasone (used in combination but not alone), or ondansetron (for acute phase).

So the correct answer is likely aprepitant. The key is that delayed CINV requires NK1 antagonists. The clinical pearl here is that aprepitant is the gold standard for delayed CINV caused by cisplatin.

**Core Concept**
Cisplatin-induced delayed emesis (occurring 24–120 hours post-chemotherapy) is mediated by substance P acting on neurokinin-1 (NK1) receptors in the central nervous system. Effective management requires a combination of 5-HT3 receptor antagonists and NK1 receptor antagonists.

**Why the Correct Answer is Right**
Aprepitant, an NK1 receptor antagonist, is the gold standard for preventing delayed chemotherapy-induced nausea and vomiting (CINV). It blocks substance P signaling in the chemoreceptor trigger zone and central emetic pathways. When combined with a 5-HT3 antagonist (e.g., ondansetron) and dexamethasone, it provides synergistic antiemetic effects, making it the agent of choice for cisplatin-induced delayed vomiting.

**Why Each Wrong Option is Incorrect**
**Option A:** Metoclopramide is a dopamine antagonist effective for acute CINV but not delayed emesis due to lack of NK1 antagonism.
**Option B:** Ondansetron (5-HT3 antagonist) is critical for acute CINV but insufficient alone for delayed emesis.
**Option D:** Dexamethasone is used adjunctively but not as monotherapy for delayed CINV.

**Clinical Pearl / High-Yield Fact**
Remember the "triple therapy" for highly emetogenic chemotherapy: **NK1 antagonist + 5-HT3 antagonist + dexamethasone**. Aprepitant (NK1 inhibitor) is indispensable for delayed CINV. Avoid relying on dopamine antagon

✓ Correct Answer: A. Aprepitant